Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China

Overview

Journal Vaccines (Basel)

Date 2022 Jul 27

PMID 35891320

Authors

Junli Li

Jinbiao Lu

Guozhi Wang

Aihua Zhao

Miao Xu

Affiliations

Soon will be listed here.

Abstract

The BCG vaccine is prepared from a weakened strain of (), a bacterium closely related to (MTB), which causes tuberculosis (TB). The vaccine was developed over 13 years, from 1908 to 1921, in the French Institut Pasteur by Léon Charles Albert Calmette and Jean-Marie Camille Guérin, who named the product Bacillus Calmette-Guérin (BCG). BCG, the only licensed vaccine currently available to prevent TB, is given to infants at high risk of TB shortly after birth to protect infants and young children from pulmonary, meningeal, and disseminated TB. The BCG vaccine, one of the safest and most widely used live attenuated vaccines in the world, recently celebrated its 100th anniversary (from 1921 to 2021); its record of use in preventing TB in China is also approaching 100 years. In 2022, a new century of BCG vaccine immunization will begin. In this article, we briefly review the history of BCG vaccine use in China, describe its current status, and offer a preliminary outlook on the future of the vaccine, to provide BCG researchers with a clearer understanding of its use in China.

Citing Articles

Pathogenic mechanisms and etiologic aspects of subspecies as an infectious cause of cutaneous melanoma.

Pierce E, Jindal C, Choi Y, Cassidy K, Efird J MedComm Oncol. 2024; 3(2).

PMID: 38831791 PMC: 11145504. DOI: 10.1002/mog2.72.

Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders.

Mathias K, Machado R, Stork S, Martins C, Kursancew A, de Rezende V Inflammation. 2024; 47(6):1902-1917.

PMID: 38664351 DOI: 10.1007/s10753-024-02018-1.

References

Colditz G, Brewer T, Berkey C, Wilson M, Burdick E, Fineberg H . Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994; 271(9):698-702. View

Dam H, TOMAN K, HITZE K, GULD J . Present knowledge of immunization against tuberculosis. Bull World Health Organ. 1976; 54(3):255-69. PMC: 2366573. View

Nieuwenhuizen N, Kulkarni P, Shaligram U, Cotton M, Rentsch C, Eisele B . The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing. Front Immunol. 2017; 8:1147. PMC: 5610719. DOI: 10.3389/fimmu.2017.01147. View

Liu X, Peng J, Hu L, Luo Y, Niu H, Bai C . A multistage mycobacterium tuberculosis subunit vaccine LT70 including latency antigen Rv2626c induces long-term protection against tuberculosis. Hum Vaccin Immunother. 2016; 12(7):1670-7. PMC: 4964814. DOI: 10.1080/21645515.2016.1141159. View

Michelsen S, Soborg B, Koch A, Carstensen L, Hoff S, Agger E . The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland. Thorax. 2014; 69(9):851-6. DOI: 10.1136/thoraxjnl-2014-205688. View

Nguipdop-Djomo P, Heldal E, Rodrigues L, Abubakar I, Mangtani P . Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis. 2015; 16(2):219-26. DOI: 10.1016/S1473-3099(15)00400-4. View

Zhang Y, Wallace Jr R, Mazurek G . Genetic differences between BCG substrains. Tuber Lung Dis. 1995; 76(1):43-50. DOI: 10.1016/0962-8479(95)90579-0. View

McShane H . Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci. 2011; 366(1579):2782-9. PMC: 3146779. DOI: 10.1098/rstb.2011.0097. View

Rosenthal S . BCG vaccination against tuberculosis. Am Rev Respir Dis. 1983; 128(4):776. DOI: 10.1164/arrd.1983.128.4.776. View

10.

Maertzdorf J, Repsilber D, Parida S, Stanley K, Roberts T, Black G . Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun. 2010; 12(1):15-22. DOI: 10.1038/gene.2010.51. View

11.

Chan P, Yang C, Chang L, Wang K, Kuo Y, Lin C . Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax. 2012; 68(3):263-8. DOI: 10.1136/thoraxjnl-2012-202208. View

12.

Gao L, Lu W, Bai L, Wang X, Xu J, Catanzaro A . Latent tuberculosis infection in rural China: baseline results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2015; 15(3):310-9. DOI: 10.1016/S1473-3099(14)71085-0. View

13.

Chard A, Gacic-Dobo M, Diallo M, Sodha S, Wallace A . Routine Vaccination Coverage - Worldwide, 2019. MMWR Morb Mortal Wkly Rep. 2020; 69(45):1706-1710. PMC: 7660669. DOI: 10.15585/mmwr.mm6945a7. View

14.

Rowland R, McShane H . Tuberculosis vaccines in clinical trials. Expert Rev Vaccines. 2011; 10(5):645-58. PMC: 3409871. DOI: 10.1586/erv.11.28. View

15.

Liu J, Tran V, Leung A, Alexander D, Zhu B . BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin. 2009; 5(2):70-8. DOI: 10.4161/hv.5.2.7210. View

16.

Behr M, Small P . A historical and molecular phylogeny of BCG strains. Vaccine. 1999; 17(7-8):915-22. DOI: 10.1016/s0264-410x(98)00277-1. View

17.

Duanmu H . [Report on fourth national epidemiological sampling survey of tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi. 2002; 25(1):3-7. View

18.

Mangtani P, Nguipdop-Djomo P, Keogh R, Trinder L, Smith P, Fine P . Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol Assess. 2017; 21(39):1-54. PMC: 5534974. DOI: 10.3310/hta21390. View

19.

Zhang W, Zhang Y, Zheng H, Pan Y, Liu H, Du P . Genome sequencing and analysis of BCG vaccine strains. PLoS One. 2013; 8(8):e71243. PMC: 3747166. DOI: 10.1371/journal.pone.0071243. View

20.

Fox G, Orlova M, Schurr E . Tuberculosis in Newborns: The Lessons of the "Lübeck Disaster" (1929-1933). PLoS Pathog. 2016; 12(1):e1005271. PMC: 4721647. DOI: 10.1371/journal.ppat.1005271. View